Preview

Medical Genetics

Advanced search
Open Access Open Access  Restricted Access Subscription Access

Search for pathogenic changes in the PIK3CA gene in women with HR+/HER- subtype breast cancer from the Republic of Bashkortostan

https://doi.org/10.25557/2073-7998.2022.09.52-55

Abstract

A study was carried out to identify the spectrum and frequency of pathogenic changes in the PIK3CA gene in the tumor tissue preparations of 60 women with hormone-dependent HER2-negative breast cancer from the Republic of Bashkortostan using the allele-specific polymerase chain reaction. As a result 32 pathogenic variants in the PIK3CA gene were identified: 18 mutations in exon 9 and 14 mutations in exon 20. The most frequent mutation was H1047R (p.His1047Arg(c.3140A>G)), which accounted for 21.6%. The second most frequent mutation was E545K (p.Glu545Lys (c.1633G>A)), which was 20%. E542K (p.Glu542Lys(c.1624G>A)), E545A (p.Glu545Ala(c.1634A>C)) mutations in exon 9 and H1047L (p.His1047Leu(c.3140A>T)) in exon 20 were identified with a frequency of 8.3%, 1.6% and 1.6% respectively. The results show a high frequency of somatic mutations in the PIK3CA gene (50%), indicating the need to identify pathogenic changes for adequate therapy of breast cancer.

About the Authors

E. M. Kagirova
Bashkir State Medical University; Personal Genomics LLC
Russian Federation


R. R. Rakhimov
Republican clinical oncologic dispensary
Russian Federation


A. V. Sultanbaev
Republican clinical oncologic dispensary
Russian Federation


R. I. Khusainova
Bashkir State University
Russian Federation


I. R. Minniahmetov
Bashkir State University
Russian Federation


References

1. ВОЗ: https://www.who.int/ru/news-room/fact-sheets/detail/breast-cancer.

2. Региональная программа Республики Башкортостан «Борьба с онкологическими заболеваниями», 2019. http://www.onkorb.ru/ru/info/borba-s-onkologicheskimi-zabolevaniyami-regionalnaya-programma-rb-.php

3. Akinleye A., Avvaru P., Furqan M., Song Y., Liu D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J Hematol Oncol. 2013;6(1):88. doi: 10.1186/1756-8722-6-88.

4. Litton J.K., Burstein H.J., Turner N.C. Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019;39:e1-e7. doi: 10.1200/EDBK_237715.

5. Martínez-Sáez, O., Chic, N., Pascual, T. et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 2020; 22(1): 45. https://doi.org/10.1186/s13058-020-01284-9

6. Соколова Т.Н., Алексахина С.Н., Янус Г.А. c cоавт. Частота и спектр мутаций PIK3CA при гормонозависимом HER2-отрицательном распространенном раке молочной железы у российских пациенток. Современная онкология. 2021; 23 (1): 61-67. DOI: https://doi.org/10.26442/18151434.2021.1.200744.

7. Pevzner A.M., Gaptulbarova K.А. et al.: Investigation of somatic PIK3CA gene mutations in breast cancer patients. JBUON 2021; 26(3): 747-752.


Review

For citations:


Kagirova E.M., Rakhimov R.R., Sultanbaev A.V., Khusainova R.I., Minniahmetov I.R. Search for pathogenic changes in the PIK3CA gene in women with HR+/HER- subtype breast cancer from the Republic of Bashkortostan. Medical Genetics. 2022;21(9):52-55. (In Russ.) https://doi.org/10.25557/2073-7998.2022.09.52-55

Views: 457


ISSN 2073-7998 (Print)